Kineta, Inc. (KANT)

Market Cap	7.35M
Revenue (ttm)	n/a
Net Income (ttm)	-20.88M
Shares Out	12.26M
EPS (ttm)	-1.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,043
Open	0.556
Previous Close	0.600
Day's Range	0.556 - 0.600
52-Week Range	0.334 - 5.390
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About Kineta

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with ad...

• Industry: Biological Products, Except Diagnostic Substances
• Employees: 13
• Stock Exchange: OTCMKTS
• Ticker Symbol: KANT

Financial Performance

In 2023, Kineta's revenue was $5.44 million, an increase of 178.65% compared to the previous year's $1.95 million. Losses were -$14.10 million, -77.76% less than in 2022.